Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
BASF (XTRA:BAS) has drawn fresh attention after the U.S. Food and Drug Administration approved Bemotrizinol as a sunscreen active ingredient, allowing the group to sell its Tinosorb S UV filter in the United States.
See our latest analysis for BASF.
For investors, the FDA approval comes as BASF trades at €50.99, with the 1-month share price return of 5.04% and a year-to-date share price return of 13.87% sitting alongside a 3-year total shareholder return of 30.87%, which suggests interest in the stock has been building over time.
If this kind of product-led story interests you, it can be worth widening the lens to other companies tied to infrastructure for advanced industries. One place to start is the 39 power grid technology and infrastructure stocks
BASF now has a fresh U.S. sunscreen catalyst in the story and a share price that has already moved. The question for you is whether to accept today’s terms or wait for a different entry point, as the valuation section sets out next.
Most Popular Narrative: 3% Undervalued
BASF’s most followed narrative points to a fair value of about €52.55 against the last close at €50.99. That small gap is built on a detailed set of earnings, margin and discount rate assumptions that go well beyond the recent FDA sunscreen catalyst.
Significant cost-savings programs (targeting €2.1 billion annual savings by end of 2026), alongside the completion of the major China Verbund investment (with project costs under budget and CapEx falling below depreciation from 2026), will meaningfully improve operating leverage and free cash flow, with cost competitiveness directly supporting improved net margins.
Want to see what sits under that fair value for BASF? The narrative leans heavily on higher margins, modest revenue growth and a different earnings multiple than today. The mix of these moving parts is what really matters.
Result: Fair Value of €52.55 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there is still the risk that prolonged weak margins in base chemicals or setbacks at major sites such as Ludwigshafen could pressure BASF and challenge this fair value story.
Find out about the key risks to this BASF narrative.
Another View on BASF’s Valuation
The analyst narrative has BASF at roughly 3% undervalued using earnings, margins and a 2029 P/E assumption. Our SWS DCF model shows a different picture, with BASF at €50.99 versus an estimated future cash flow value of €116.34, which implies a wide gap. Which version of “value” do you consider more relevant?
Look into how the SWS DCF model arrives at its fair value.
BAS Discounted Cash Flow as at Aug 2026 Next Steps
If the mixed signals on BASF leave you unsure, act while the details are fresh and test the assumptions yourself by weighing the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond BASF?
Do not stop with BASF. A few focused stock lists can quickly surface other candidates that fit the kind of quality, value and resilience you are looking for.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BAS.DE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com